Cargando…

A signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT

Targeted cancer therapy aims to disrupt aberrant cellular signalling pathways. Biomarkers are surrogates of pathway state, but there is limited success in translating candidate biomarkers to clinical practice due to the intrinsic complexity of pathway networks. Systems biology approaches afford bett...

Descripción completa

Detalles Bibliográficos
Autores principales: Bown, James L., Shovman, Mark, Robertson, Paul, Boiko, Andrei, Goltsov, Alexey, Mullen, Peter, Harrison, David J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444693/
https://www.ncbi.nlm.nih.gov/pubmed/27302920
http://dx.doi.org/10.18632/oncotarget.8747
_version_ 1783238744452628480
author Bown, James L.
Shovman, Mark
Robertson, Paul
Boiko, Andrei
Goltsov, Alexey
Mullen, Peter
Harrison, David J.
author_facet Bown, James L.
Shovman, Mark
Robertson, Paul
Boiko, Andrei
Goltsov, Alexey
Mullen, Peter
Harrison, David J.
author_sort Bown, James L.
collection PubMed
description Targeted cancer therapy aims to disrupt aberrant cellular signalling pathways. Biomarkers are surrogates of pathway state, but there is limited success in translating candidate biomarkers to clinical practice due to the intrinsic complexity of pathway networks. Systems biology approaches afford better understanding of complex, dynamical interactions in signalling pathways targeted by anticancer drugs. However, adoption of dynamical modelling by clinicians and biologists is impeded by model inaccessibility. Drawing on computer games technology, we present a novel visualization toolkit, SiViT, that converts systems biology models of cancer cell signalling into interactive simulations that can be used without specialist computational expertise. SiViT allows clinicians and biologists to directly introduce for example loss of function mutations and specific inhibitors. SiViT animates the effects of these introductions on pathway dynamics, suggesting further experiments and assessing candidate biomarker effectiveness. In a systems biology model of Her2 signalling we experimentally validated predictions using SiViT, revealing the dynamics of biomarkers of drug resistance and highlighting the role of pathway crosstalk. No model is ever complete: the iteration of real data and simulation facilitates continued evolution of more accurate, useful models. SiViT will make accessible libraries of models to support preclinical research, combinatorial strategy design and biomarker discovery.
format Online
Article
Text
id pubmed-5444693
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-54446932017-06-01 A signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT Bown, James L. Shovman, Mark Robertson, Paul Boiko, Andrei Goltsov, Alexey Mullen, Peter Harrison, David J. Oncotarget Research Paper Targeted cancer therapy aims to disrupt aberrant cellular signalling pathways. Biomarkers are surrogates of pathway state, but there is limited success in translating candidate biomarkers to clinical practice due to the intrinsic complexity of pathway networks. Systems biology approaches afford better understanding of complex, dynamical interactions in signalling pathways targeted by anticancer drugs. However, adoption of dynamical modelling by clinicians and biologists is impeded by model inaccessibility. Drawing on computer games technology, we present a novel visualization toolkit, SiViT, that converts systems biology models of cancer cell signalling into interactive simulations that can be used without specialist computational expertise. SiViT allows clinicians and biologists to directly introduce for example loss of function mutations and specific inhibitors. SiViT animates the effects of these introductions on pathway dynamics, suggesting further experiments and assessing candidate biomarker effectiveness. In a systems biology model of Her2 signalling we experimentally validated predictions using SiViT, revealing the dynamics of biomarkers of drug resistance and highlighting the role of pathway crosstalk. No model is ever complete: the iteration of real data and simulation facilitates continued evolution of more accurate, useful models. SiViT will make accessible libraries of models to support preclinical research, combinatorial strategy design and biomarker discovery. Impact Journals LLC 2016-05-18 /pmc/articles/PMC5444693/ /pubmed/27302920 http://dx.doi.org/10.18632/oncotarget.8747 Text en Copyright: © 2017 Bown et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research Paper
Bown, James L.
Shovman, Mark
Robertson, Paul
Boiko, Andrei
Goltsov, Alexey
Mullen, Peter
Harrison, David J.
A signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT
title A signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT
title_full A signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT
title_fullStr A signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT
title_full_unstemmed A signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT
title_short A signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT
title_sort signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: sivit
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444693/
https://www.ncbi.nlm.nih.gov/pubmed/27302920
http://dx.doi.org/10.18632/oncotarget.8747
work_keys_str_mv AT bownjamesl asignalingvisualizationtoolkittosupportrationaldesignofcombinationtherapiesandbiomarkerdiscoverysivit
AT shovmanmark asignalingvisualizationtoolkittosupportrationaldesignofcombinationtherapiesandbiomarkerdiscoverysivit
AT robertsonpaul asignalingvisualizationtoolkittosupportrationaldesignofcombinationtherapiesandbiomarkerdiscoverysivit
AT boikoandrei asignalingvisualizationtoolkittosupportrationaldesignofcombinationtherapiesandbiomarkerdiscoverysivit
AT goltsovalexey asignalingvisualizationtoolkittosupportrationaldesignofcombinationtherapiesandbiomarkerdiscoverysivit
AT mullenpeter asignalingvisualizationtoolkittosupportrationaldesignofcombinationtherapiesandbiomarkerdiscoverysivit
AT harrisondavidj asignalingvisualizationtoolkittosupportrationaldesignofcombinationtherapiesandbiomarkerdiscoverysivit
AT bownjamesl signalingvisualizationtoolkittosupportrationaldesignofcombinationtherapiesandbiomarkerdiscoverysivit
AT shovmanmark signalingvisualizationtoolkittosupportrationaldesignofcombinationtherapiesandbiomarkerdiscoverysivit
AT robertsonpaul signalingvisualizationtoolkittosupportrationaldesignofcombinationtherapiesandbiomarkerdiscoverysivit
AT boikoandrei signalingvisualizationtoolkittosupportrationaldesignofcombinationtherapiesandbiomarkerdiscoverysivit
AT goltsovalexey signalingvisualizationtoolkittosupportrationaldesignofcombinationtherapiesandbiomarkerdiscoverysivit
AT mullenpeter signalingvisualizationtoolkittosupportrationaldesignofcombinationtherapiesandbiomarkerdiscoverysivit
AT harrisondavidj signalingvisualizationtoolkittosupportrationaldesignofcombinationtherapiesandbiomarkerdiscoverysivit